e-ISSN: 2717-7149
  • Home
  • About The Journal
  • Editorial Board
  • Instructions for Authors
  • Contact
Current Issue
Ahead Of Print
Archive
Search
Most Popular
Download Articles Read Articles
Retina Arter Tıkanıklıkları ve Tedavisi...
Santral Retinal Ven Tıkanıklığı Güncel Tedavisi...
Central Retinal Artery Occlusion As the Cause of Unilateral Concentric Narrowing of Visual Field and Presence of Cilioretinal Artery...
Bilateral Optic Disc Drusen
Vascular Endothelial Growth Factor and Anti VEGF Agents...
Central Retinal Artery Occlusion As the Cause of Unilateral Concentric Narrowing of Visual Field and Presence of Cilioretinal Artery...
Retina Arter Tıkanıklıkları ve Tedavisi...
Morning Glory Syndrome Associated with Retinochoroidal Coloboma...
Santral Retinal Ven Tıkanıklığı Güncel Tedavisi...
Bilateral Optic Disc Drusen
PureSee Kesintisiz Yüksek Kalitede Görüş
Retina-Vitreous 2023 , Vol 32 , Num 3
Turkish Abstract Abstract Free Full Text English Similar Articles Mail to Author
Effectiveness of Three Loading Dose of Intravitreal Bevacizumab in Central Diabetic Macular Edema
Bora Yuksel1, Tuncay Kusbeci2, Batuhan Aygoren3, Okan Akmaz4, Faruk Bicak5
1Doc. Dr., University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Department of Ophthalmology, Bozyaka-İzmir-Türkiye
2Prof. Dr., University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Department of Ophthalmology, Bozyaka-İzmir-Türkiye
3Resident Dr., University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Department of Ophthalmology, Bozyaka-İzmir-Türkiye
4FEBO, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Department of Ophthalmology, Bozyaka-İzmir-Türkiye
5Ophthalmologist, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Department of Ophthalmology, Bozyaka-İzmir-Türkiye
DOI : 10.37845/ret.vit.2023.32.31 Purpose: To assess efficacy of three loading dose of bevacizumab in central diabetic macular edema.

Materials and Methods: This retrospective study included 30 eyes of 23 patients who were given three loading doses of monthly intravitreal bevacizumab (1.25 mg/mL) for central DDME between February, 2019 and January, 2021. The study included treatment-naive eyes with bestcorrected visual acuity (BCVA) ? least 5 letters at baseline. In all cases, central macular thickness (CMT) was measured using spectral-domain optical coherence tomography (SD-OCT: Spectralis, Heidelberg Engineering, Heidelberg, Germany). The BCVA was assessed using geometric chart at 4 meters. BCVA, CMT and intraocular pressure measurements as well as biomicroscopy and fundus examination were performed at each control visit. Primary efficacy outcome was visual acuity gain (in letters) and CMT reduction. Data were analyzed using Paired samples t test, ANOVA and Pearson?s correlation analysis.

Findings: Mean age was 59.0±8.1 years in the study population. Mean BCVA was 19.6±10.7 letters while mean CMT was 479.0±10.6 ?m at baseline. The vision was improved to 22.8±10.1 letters (p=0.007) while mean CMT was decreased t0 453.9±137.9 ?m (p=0.163) after first injection (Paired samples t test). The vision was improved to 25.1±9.4 letters (p=0.007) and mean CMT was decreased to 420.8±130.5 ?m (p=0.016) after second injection; and 28.6±9.9 letters (p=0.000) and 393±146.0 ?m (p=0.002) after third injection. The letter gain was 9 letters. It was found that ?3 orders improvement was achieved in 9 eyes )30%) whereas 2 orders in 8 eyes (26.7%) and 1 order in 9 eyes (30.0%). There was no response or decreased vision in 4 eyes (13.3%).

Conclusion: Treatment with three loading dose of monthly bevacizumab is an effective first-line treatment ensuring visual and anatomic improvement in DME. Keywords : Diabetic macular edema, Bevacizumab, Intravitreal injection

PureSee Kesintisiz Yüksek Kalitede Görüş
Home
About The Journal
Editorial Board
Instructions for Authors
Contact